1. Home
  2. Current Affairs
  3. Current News
  4. India Approves First Dengue Vaccine

India Approves First Dengue Vaccine

  • 21 Jul 2026

In July 2026, India approved its first dengue vaccine, QDENGA, providing a new tool to reduce the country's growing dengue burden.

Key Points

  • Regulatory Approval: The Drug Controller General of India (DCGI) granted market authorisation to QDENGA, developed by Takeda Biopharmaceuticals India.
  • Eligible Population: The vaccine is approved for people aged 4–60 years, irrespective of previous dengue infection.
  • No Pre-screening Required: Unlike some earlier dengue vaccines, QDENGA does not require pre-vaccination screening for past dengue infection.
  • Vaccine Type: QDENGA is a live-attenuated tetravalent vaccine that provides protection against all four dengue virus serotypes (DENV-1, DENV-2, DENV-3 and DENV-4).
  • Global Recognition: The vaccine has been approved in over 40 countries and has received WHO prequalification, confirming its quality, safety and efficacy.
  • International Procurement: WHO prequalification makes the vaccine eligible for procurement by international agencies such as UNICEF and the Pan American Health Organization (PAHO).